#Japan - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification [FINAL]

 Sea Otters in Hokkaido Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6551

____

Re-Emergence of #Usutu Virus and Spreading of #WestNile Virus #Neuroinvasive Infections During the 2024 Transmission Season in #Croatia

Abstract

Neuroinvasive arboviruses such as tick-borne encephalitis virus (TBEV), West Nile virus (WNV), Usutu virus (USUV), and Toscana virus (TOSV) have (re-)emerged with increasing incidence and geographic range. We analyzed the epidemiology of arboviral infections in Croatia during the 2024 transmission season. A total of 154 patients with neuroinvasive diseases (NID), 1596 horses, 69 dead birds, and 7726 mosquitoes were tested. Viral RNA was detected using RT-qPCR. IgM/IgG-specific antibodies were detected using commercial ELISA or IFA, with confirmation of cross-reactive samples by virus neutralization test. RT-qPCR-positive samples were Sanger sequenced. Arboviral etiology was confirmed in 33/21.42% of patients with NID. WNV was most frequently detected (17/11.03%), followed by TBEV (10/6.49%), USUV (5/3.24%), and TOSV (1/0.64%). WNV infections were reported in regions previously known as endemic, while in one continental county, WNV was recorded for the first time. USUV infections re-emerged after a six-year absence. In addition to human cases, acute WNV infections were recorded in 11/395 (2.78%) of horses and two dead crows. WNV IgG seropositivity was detected in 276/1168 (23.63%) and TBEV IgG seropositivity in 68/428 (15.88%) horses. None of the tested mosquito pools were positive for WNV and USUV RNA. Phylogenetic analysis showed the circulation of WNV lineage 2 and Usutu Europe 2 lineage. Climate conditions in 2024 in Croatia were classified as extremely warm, which could, at least in part, impact the quite intense arboviral season. The spreading of flaviviruses in Croatia highlights the need for continuous surveillance in humans, animals, and vectors (“One Health”).

Source: Viruses, https://www.mdpi.com/1999-4915/17/6/846

____

Broad geographical #circulation of a novel #vesiculovirus in #bats in the #Mediterranean region

Abstract

Bats are the natural reservoirs for a variety of emerging and re-emerging viruses. Among them, rabies virus (genus Lyssavirus, family Rhabdoviridae) is one of the first and most emblematic described in these animals. Since its first description, several new bat lyssaviruses have been regularly identified. In addition to lyssaviruses, other bat rhabdoviruses have also been discovered, including members of the genera Vesiculovirus, Ledantevirus and, more recently, Alphanemrhavirus and Tupavirus. However, the family Rhabdoviridae is one of the most abundant and diverse viral families, with 434 officially recognized species, divided into 5 subfamilies and 56 different genera. The number of rhabdoviruses associated with bats is therefore probably higher than that currently available. In this study, we first developed and validated a combined nested RT-qPCR technique (pan-rhabdo RT-nqPCR) dedicated to the broad detection of animal rhabdoviruses. After validation, this technique was used for a large retrospective screening of archival bat samples (n = 1962), including blood (n = 816), brain (n = 723) and oral swab (n = 423). These samples were collected from various bat species over a 12-year period (2007–2019) in 9 different countries in Europe and Africa. A total of 23 samples (1.2%) from bat species Miniopterus schreibersii, Rhinolophus euryale and Rhinolophus ferrumequinum tested positive for rhabdovirus infection, including 17 (2.1%) blood and 6 (1.4%) oral swab samples, all collected from bats originating from the Mediterranean region. Complete virus genome sequences were obtained by next-generation sequencing for most of the positive samples. Molecular and phylogenetic analysis of these sequences demonstrated that these virus isolates, named Mediterranean bat virus (MBV), were closely related and represented a new species, Mediterranean vesiculovirus, within the Vesiculovirus genus. MBV was more specifically related to other bat vesiculoviruses previously described from China and North America, together clustering into a distinct group of bat viruses within this genus. Interestingly, our results suggest that MBV is widespread, at least in the western part of the Mediterranean region, where it circulates in the blood of several bat species. These results expand the host range and viral diversity of bat vesiculoviruses, and pave the way for further studies to determine the transmission route and dissemination dynamics of these viruses in bat colonies, as well as to assess their potential threat to public health.

Author summary

Bats are the natural hosts for a wide variety of viruses, particularly those belonging to the family Rhabdoviridae, which include the lyssaviruses, the etiological agents of rabies. This viral family is one of the most abundant and diverse, with 434 officially recognized species. However, the current diversity of these viruses in bats remains poorly understood. To address this, we developed a new method for detecting rhabdoviruses in bat samples collected over a period of 12 years in several European and African countries. From nearly 2,000 samples, we discovered a new rhabdovirus, which was named Mediterranean bat virus (MBV). MBV has been detected in the blood and oral swabs of specific bat species (Rhinolophus sp. and Miniopterus schreibersii) living on both sides of the Mediterranean region. Based on phylogenetic analysis, we determined that MBV represented a unique group within the genus Vesiculovirus, but still related to other bat vesiculoviruses discovered in China and North America. These results expand the host range and viral diversity of bat rhabdoviruses, and pave the way for further studies to determine the transmission route and dissemination dynamics of these viruses in bat colonies, as well as to assess their potential threat to public health.

Source: PLoS Neglected Tropical Diseases, https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0013172

____

#Management and #outcomes of #children hospitalised with #COVID19 including Incidental and Nosocomial infections in #Australia 2020-2023: a national surveillance study

Highlights

• Acute COVID-19 usually causes mild illness even in young and immunosuppressed children

• Nosocomial SARS-CoV-2 infection is associated with more severe disease

• Concurrent serious bacterial infection is rare in children admitted with acute COVID-19.

ABSTRACT

Background

Management and outcomes of children hospitalised with acute SARS-CoV-2 infection may differ throughout the pandemic or with admission type (clinical COVID-19, incidental COVID-19 or nosocomial infection).

Objectives

Describe the severity, management and outcomes of hospitalised children with acute SARS-CoV-2 infection in Australia across the first 4 years of the pandemic and compare between admission types, SARS-CoV-2 variants, age groups and immune status.

Study design

A multi-centre prospective cohort study of 6,009 children aged 0-16 years between January 2020 to June 2023.

Results

Most children (84.3%) did not receive respiratory support, 33.4% received antibiotics and 8% were admitted to intensive care unit (ICU). Infants <6 months old were more likely to be admitted with clinical COVID than older children (12-16 years). Older children were more likely to receive antibiotics (27.8% vs 43.9%), corticosteroids (11.3% vs 34.1) or ICU admission (5.2% vs 13.5%). Compared to immunocompetent children, the immunosuppressed (7.7%) were more likely to have nosocomial infection (9.5% v 3.9%), receive antibiotics (57% vs 25%) or antivirals (18% vs 4.4%), but less likely to require respiratory support (93.4% vs 83.8%) or ICU admission (3.5% vs 8%). Children with nosocomial SARS-CoV-2 infection had higher rates of invasive ventilation (8%) and ICU admission (21%) compared to those with clinical (2.1% and 7.1% respectively) or incidental COVID-19 (4.8% and 9.1% respectively).

Conclusions

Acute COVID-19 generally caused mild disease in hospitalised children, with management and outcomes differing by age and admission type. Similar outcomes were observed across the pandemic. Nosocomial SARS-CoV-2 infection was associated with more severe disease.

Source: Journal of Clinical Virology, https://www.sciencedirect.com/science/article/abs/pii/S1386653225000666?dgcid=rss_sd_all

____

#Mpox in #Africa: What we know and what is still lacking

Abstract

Emerging as a major global health threat, Mpox previously known as Monkeypox has drawn attention due to a worrying surge in cases. This zoonotic disease, native to Central and West Africa, is marked by fever, rash, and lymphadenopathy and is primarily spread through direct contact with infected animals or people and indirectly through contaminated objects. Recent studies have indicated possible sexual transmission, underscoring how human behavior and environmental changes are increasing its prevalence, even though human-to-human transmission is less efficient than that of smallpox. Mpox is endemic in several African countries, and currently, the infection has spread in non-endemic countries, including Rwanda, Uganda, and Kenya. Democratic Republic of Congo is the epicenter of the current Mpox outbreak. From January 1, 2022, to August 6, 2024, sixteen African countries reported Mpox outbreak. Several factors, including population immunity deficiencies and changes to the environment and ecology, have led to the widespread of Mpox in Africa. Challenges such as the fragile healthcare system, limited vaccine availability and access, weak surveillance, and low public awareness poses difficulty in containing the infection in affected countries. Given the potential of Mpox to disrupt several sectors including health systems, which may ultimately reverse progress in achieving the sustainable development goals by 2030. It is imperative for countries, both within and outside Africa, to extend financial aid and human resources to combat the infection effectively.

Source: PLoS Neglected Tropical Diseases, https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0013148

____

#UK - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

A small commercial flock of 69 chickens, 23 ducks and 5 geese. Increased mortality reported in chickens as well as a drop in egg production in the ducks. Samples were taken and tested positive for HPAI H5N1. Location: Kirklees, West Yorkshire, England.

Source: WOAH, https://wahis.woah.org/#/in-review/6552

____

Ten Previously Unassigned #Human #Cosavirus #Genotypes Detected in Feces of #Children with Non-Polio #AFP in #Nigeria in 2020

Abstract

Since its discovery via metagenomics in 2008, human cosavirus (HCoSV) has been detected in the cerebrospinal fluid (CSF) and feces of humans with meningitis, acute flaccid paralysis (AFP), and acute gastroenteritis. To date, 34 HCoSV genotypes have been documented by the Picornaviridae study group. However, the documented genetic diversity of HCoSV in Nigeria is limited. Here we describe the genetic diversity of HCoSV in Nigeria using a metagenomics approach. Archived and anonymized fecal specimens from children (under 15 years old) diagnosed with non-polio AFP from five states in Nigeria were analyzed. Virus-like particles were purified from 55 pools (made from 254 samples) using the NetoVIR protocol. Pools were subjected to nucleic acid extraction and metagenomic sequencing. Reads were trimmed and assembled, and contigs classified as HCoSV were subjected to phylogenetic, pairwise identity, recombination analysis, and, when necessary, immuno-informatics and capsid structure prediction. Fifteen pools yielded 23 genomes of HCoSV. Phylogenetic and pairwise identity analysis showed that all belonged to four species (eleven, three, three, and six members of Cosavirus asiani, Cosavirus bepakis, Cosavirus depakis, and Cosavirus eaustrali, respectively) and seventeen genotypes. Ten genomes belong to seven (HCoSV-A3/A10, A15, A17, A19, A24, D3, and E1) previously assigned genotypes, while the remaining thirteen genomes belonged to ten newly proposed genotypes across the four HCoSV species, based on the near-complete VP1 region (VP1*) of the cosavirus genome. Our analysis suggests the existence of at least seven and eight Cosavirus bepakis and Cosavirus eaustrali genotypes, respectively (including those described here). We report the first near-complete genomes of Cosavirus bepakis and Cosavirus depakis from Nigeria, which contributes to the increasing knowledge of the diversity of HCoSV, raising the number of tentative genotypes from 34 to over 40. Our findings suggest that the genetic diversity of HCoSV might be broader than is currently documented, highlighting the need for enhanced surveillance.

Source: Viruses, https://www.mdpi.com/1999-4915/17/6/844

____

Impact of #serum versus #anticoagulant-containing #plasma on #influenza virus #neuraminidase-based serological assays

Abstract

The influenza virus neuraminidase (NA) is a promising target for next-generation influenza vaccines but standardized protocols for NA-based serological assays are lacking. Previous studies have demonstrated discordant results from haemagglutination inhibition and live virus microneutralization assays when comparing matched serum and plasma samples. It is therefore important to consider is the choice of serum or plasma samples in assays measuring influenza virus NA-specific antibodies. Here, we compared antibody titres against influenza A and B virus NAs in matched serum and different types of plasma using an enzyme-linked lectin assay (ELLA) and an enzyme-linked immunosorbent assay (ELISA). We observed good correlations between titres determined in serum and different types of plasma. However, there was variable and often poor agreement in the nominal titre values obtained from serum and different kinds of plasma in both ELLA and ELISA, with plasma samples often resulting in lower titres compared to serum samples. We also found differences in NA-specific responses to seasonal influenza vaccination assessed in serum versus plasma. Overall, our data demonstrate discrepancies between NA-specific antibody measurements in serum and plasma. We recommend the consistent use of serum as an important part of standardising NA-based serological assays.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.06.07.658460v1

____

#Lanka virus, a #Mus booduga-borne #orthohantavirus #infection-associated febrile illness in #SriLanka

Abstract

Background

In Sri Lanka, a high seroprevalence of antibodies against hantaviruses was reported in communities affected by chronic kidney disease of unknown etiology (CKDu). Recently, two rodent-borne hantaviruses, Lanka virus and Anjozorobe virus, were identified in these areas. However, it is unclear which virus is the source of infection in humans, and its pathogenicity is unknown.

Methodology/principal findings

A total of 181 sera from febrile patients from two CKDu-endemic regions, Girandurukotte and Polonnaruwa, were examined and Lanka virus genome was detected in two IgM-positive febrile patients. Of 76 serum samples from patients with fever of unknown etiology collected during 2016 examined to identify hantavirus genomes, antibodies, and serotypes, 10 were IgG-positive with five of them having IgM also. They were all without clinical features of hemorrhagic fever with renal syndrome, but three patients required treatment in the intensive care unit. A serotyping strategy was established based on the antigenic difference of the glycoprotein Gn of Lanka and Anjozorobe viruses. Using this method, febrile patients were found to be infected with the Lanka virus and none of the patient sera showed Anjozorobe virus infection pattern. Additionally, a total of 373 previously diagnosed seropositive serum samples from CKDu patients and healthy residents were serotyped to categorize 87% of seropositives as Lanka virus infection.

Conclusions/significance

Lanka virus carried by little Indian field mouse (Mus booduga) is transmitted to humans, likely causing febrile illness occasionally while leading to severe disease in some of the febrile patients.

Author summary

Hantaviruses are known to be transmitted by rodents and cause severe diseases such as hemorrhagic fever with renal syndrome (HFRS) in humans. Although there have been few reports of typical HFRS in Sri Lanka, there are many antibody-positive individuals. The antibody positivity rate is particularly high in patients with chronic kidney disease by unknown etiology (CKDu), and the relationship between hantavirus infection and CKDu is being discussed. Meanwhile, rodent surveys have identified Lanka virus in little Indian field mouse (Mus booduga) and Anjozorobe virus in black rat (Rattus rattus) in Sri Lanka. However, it was unclear which virus was infecting the humans and its pathogenicity. This study showed that hantavirus infections in Sri Lanka could be asymptomatic or cause common fever-like symptoms and rarely require treatment in an ICU. It was also shown that the main source of infection is Lanka virus. This study leads us to the starting line of clarifying the Lanka virus-related health risks, such as its association with CKDu.

Source: PLoS Neglected Tropical Diseases, https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0013169

____

Evaluation of #country #preparedness for #Nipah and avian #influenza #zoonotic viral #threats in #Bangladesh

Highlights

• Systematic and routine monitoring antigenic drift and shift of AIV in wild birds and poultry is needed.

• Community-based surveillance is key for improving NiV case detection.

• Integrated surveillance across One Health sectors is required.

• Lab upgrades to BSL-3 are needed for enhanced biosafety and diagnostics.

Abstract

Nipah and avian influenza viruses (NiV and AIV) are priority zoonotic pathogens in Bangladesh and are also important globally because of their pandemic potential. To understand current strengths, areas for improvement, and opportunities to enhance preparedness for NiV and AIV in Bangladesh, as part of the USAID STOP Spillover program, 47 relevant stakeholders were surveyed, and two country leads of the primary surveillance systems were interviewed. Data was collected focusing on four different areas: research projects, surveillance systems, laboratories, and outbreak risk management systems. Despite progress in recent years, our study reveals significant gaps in preparedness, detection, and response capacities across sectors and highlights the importance of prioritizing extended and targeted surveillance, biosafety solutions for laboratories, and early event detection for resilient defenses against these viruses using a One Health framework.

Source: One Health, https://www.sciencedirect.com/science/article/pii/S2352771425001119?via%3Dihub

____

Promising Effects of #Duck #Vaccination against Highly Pathogenic Avian #Influenza, #France 2023–2024

Abstract

Highly pathogenic avian influenza causes substantial poultry losses and zoonotic concerns globally. Duck vaccination against highly pathogenic avian influenza began in France in October 2023. Our assessment predicted that 314–756 outbreaks were averted in 2023–2024, representing a 96%–99% reduction in epizootic size, likely attributable to vaccination.

Source: US Centers for Disease Control and Prevention, https://wwwnc.cdc.gov/eid/article/31/7/24-1445_article

____

Anti #Matrix Protein 1 Monoclonal #Antibody Neutralizes #Influenza A Virus Subtypes

Abstract

Background: 

Research on monoclonal antibodies (mAb) targeting conserved internal proteins of influenza is limited.The matrix protein 1 (M1), the most abundant and conserved internal protein, serves as an endoskeleton bridging cytoplasmic tails of envelope glycoproteins haemagglutinin (HA), neuraminidase (NA) and matrix protein 2 (M2) with viral ribonucleoprotein particles (vRNPs). Clinical studies reveal significant M1 antibody responses post-infection and vaccination, with demonstrated B and T cell recognition. Our study examines 2B-B10-G9, our lab-synthesized mAb targeting conserved linear epitope of M1 at the C-terminal domain (CTD). 

Methods: 

Binding of 2B-B10-G9 to the purified influenza A viruses (IAV) and influenza B viruses (IBV) were assessed using SDS-PAGE and Western blotting with Image J analysis. Purified viruses included IAV (H1N1, Pandemic (H1N1) 2009 (H1N1pdm09), and H3N2 subtypes) and IBV which was first isolated in 1940 (B/Lee/40), and B/Victoria lineage. Cytotoxicity of 2B-B10-G9 on the Madin-Darby canine kidney (MDCK) cells was studied by MTT (3-(4, 5-dimethylthiazol-2)-2, 5-diphenyltetrazolium bromide) cell proliferation assay to establish in vitro and in ovo treatment doses. In ovo studies involved injecting 2B-B10-G9 into the allantoic cavity of specific pathogen free (SPF) 10-day-old embryonated chicken eggs (ECE) immediately post-infection with influenza A/Puerto Rico/8/1934 (H1N1) followed by RT-qPCR analysis of the virulence genes HA, NA, and PB1 expressions in the allantoic fluid (AF) 48 hours post-infection. 

Results: 

mAb 2B-B10-G9 shows significantly stronger binding to the M1 protein of H1N1 subtype of IAV with respect to H3N2 subtype of IAV (p < 0.001), and it has significantly stronger binding to the M1 protein of H1N1 subtype of IAV with respect to H1N1pdm09 subtype, IBV including B/Lee/40, B/Victoria lineage. (p< 0.0001) mAb 2B-B10-G9 at dose of 40 ug/ml which was determined as an optimal dose according to the MTT assay, significantly reduced plaque-forming units (PFU)/ml of IAV H1N1 and H3N2 subtypes in vitro (p< 0.0001). In ovo treatment of IAV H1N1 subtype at the same dose 40 ug/ml, significantly suppressed the virulence genes HA, NA, and PB1 expressions compared to the untreated group (p< 0.0001, p< 0.001, p< 0.0001, respectively) and mouse isotype IgG1 mAb treated groups (p< 0.01). 

Conclusions: 

These findings highlight that anti-M1 mAb 2B-B10-G9, targeting conserved linear epitope at the CTD of M1 protein, might be considered as a possible therapeutic option for IAV H1N1 and H3N2 subtypes related to its significant recognition and binding, viral neutralization and suppression of expression of virulence genes including HA, NA and PB1.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.06.09.658662v1

____

#Oseltamivir #Treatment vs Supportive Care for Seasonal #Influenza Requiring #Hospitalization

Key Points

-- Question:  In adults with influenza requiring admission to hospital, is oseltamivir treatment within the first 2 days of admission, when compared with supportive care without oseltamivir, associated with a decreased risk of death in hospital?

-- Findings: In this cohort study of 11 073 patients hospitalized with influenza, oseltamivir treatment was associated with an adjusted risk reduction of 1.8% for in-hospital mortality when compared with supportive care.

-- Meaning: The findings of this study support current guidelines that recommend oseltamivir treatment for patients admitted to hospital with influenza; clinical trials should be conducted to generate better quality evidence.

Abstract

Importance  

Current guidelines recommend oseltamivir treatment for all patients hospitalized with influenza, but this guidance is based on suboptimal evidence.

Objective  

To evaluate outcomes associated with oseltamivir treatment when compared with supportive care for severe seasonal influenza requiring hospitalization.

Design, Setting, and Participants  

This retrospective cohort study using target trial emulation included adult patients admitted to hospital with influenza from 30 hospitals in Ontario, Canada, from January 2015 to June 2023. Data were analyzed from November 2024 to March 2025.

Exposure  

Oseltamivir treatment on hospital day 0 or 1 vs supportive care without oseltamivir.

Main Outcome and Measures  

The primary outcome was in-hospital mortality. Secondary outcomes included time to being discharged alive and readmission within 30 days. Overlap weighting of propensity scores was used to balance covariates, and a competing risk model was used to compare time to being discharged alive.

Results  

Of 11 073 patients (mean [SD] age, 72.6 [16.8] years; 5793 female [52.3%]), there were 7632 patients (68.9%) and 3441 patients (31.1%) in the oseltamivir and supportive care groups, respectively. In hospital, 268 patients (3.5%) and 168 patients (4.9%) in the oseltamivir and supportive care groups died, respectively, with an adjusted risk difference of −1.8% (95% CI, −2.8% to −0.9%; P < .001). The oseltamivir treatment group was more likely to be discharged alive (adjusted subdistribution hazard ratio, 1.20; 95% CI, 1.15 to 1.25; P < .001). After discharge, 645 patients (8.5%) and 336 patients (9.8%) were readmitted in the oseltamivir and supportive care groups, respectively, with an adjusted risk difference of −1.5% (95% CI, −2.8% to −0.2%; P = .02).

Conclusions and Relevance  

In this cohort study of patients hospitalized with influenza, oseltamivir treatment was associated with a lower in-hospital mortality risk, earlier discharge, and lower readmission rate, supporting evidence for the current guideline recommendation of oseltamivir treatment for severe influenza. Clinical trials are needed to definitively answer this question.

Source: JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158

____

Monotherapy with #antibody 1C3 partially protects #Ebola virus-exposed #macaques

ABSTRACT

A cocktail of human monoclonal antibodies 1C3 and 1C11 previously protected macaques from a lethal exposure to either Ebola virus (EBOV) or Sudan virus (SUDV). 1C3 is of particular interest because its paratope strongly binds with unique stoichiometry to the glycoprotein head of several orthoebolaviruses, resulting in neutralization of EBOV and SUDV. Therefore, we evaluated the protective activity of 1C3 as a standalone therapeutic in macaques exposed to either EBOV or SUDV. Two doses of 1C3 monotherapy, administered 4 and 7 days post-exposure, did not protect SUDV-exposed macaques and partially protected EBOV-exposed macaques. Notably, in a macaque that succumbed to EBOV infection, we identified two mutually exclusive escape mutations that emerged immediately after the first dose and resulted in two amino acid changes at the 1C3 binding site. We also detected a subconsensus treatment-emergent mutation likely affecting the 1C3 binding site in all three deceased SUDV-exposed macaques. Our findings highlight combination treatment with 1C11 as critical for protection, particularly against SUDV, and in vivo activity of unpartnered 1C3 as susceptible to rapid EBOV and SUDV escape under therapeutic pressure.

IMPORTANCE

A cocktail of human monoclonal antibodies 1C3 and 1C11 previously protected macaques exposed to a lethal dose of either Ebola virus (EBOV) or Sudan virus (SUDV). Since the unique binding characteristics of 1C3 are of particular interest, we evaluated its protective activity as monotherapy in macaques exposed to either EBOV or SUDV. Two doses of 1C3 alone did not protect SUDV-exposed macaques and only partially protected EBOV-exposed macaques. Importantly, failure to protect was associated with the rapid emergence of previously in vitro-identified escape mutations at the 1C3 binding site, highlighting the importance of its use in combination with 1C11 for protection against fatal disease outcome and avoiding rapid EBOV and SUDV escape. Findings have broader implications for the wise use of combination-based monoclonal antibody therapeutics to improve outcomes and prevent resistance in filovirid diseases.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.00296-25?af=R

____

Long-term serial passaging of #SARS-CoV-2 reveals #signatures of convergent #evolution

ABSTRACT

Understanding viral evolutionary dynamics is crucial to pandemic responses, prediction of virus adaptation over time, and virus surveillance for public health strategies. Whole-genome sequencing (WGS) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has enabled fine-grained studies of virus evolution in the human population. Serial passaging in vitro offers a complementary controlled environment to investigate the emergence and persistence of genetic variants that may confer selective advantage. In this study, nine virus lineages, including four “variants of concern” and three former “variants under investigation,” were sampled over ≥33 serial passages (range 33–100) in Vero E6 cells. WGS was used to examine virus evolutionary dynamics and identify key mutations with implications for fitness and/or transmissibility. Viruses accumulated mutations regularly during serial passaging. Many low-frequency variants were lost, but others became fixed, suggesting either in vitro benefits or at least a lack of deleterious effect. Mutations arose convergently both across passage lines and when compared with contemporaneous SARS-CoV-2 clinical sequences. These mutations included some that are hypothesized to drive lineage success through host immune evasion (e.g., S:A67V, S:H655Y). The appearance of these mutations in vitro suggested key mutations can arise convergently even in the absence of a multicellular host immune response through mechanisms other than immune-driven mutation. Such mutations may provide other benefits to the viruses in vitro, or arise stochastically. Our quantitative investigation into SARS-CoV-2 evolutionary dynamics spans the greatest number of serial passages to date and will inform measures to reduce the effects of SARS-CoV-2 infection on the human population.

IMPORTANCE

The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a challenge for long-term public health efforts to minimize the effects of coronavirus disease 2019. Whole-genome sequencing of outbreak cases has enabled global contact tracing efforts and the identification of mutations of concern within the virus’ genome. However, complementary approaches are necessary to inform our understanding of virus evolution and clinical outcomes. Here, we charted the evolution of the virus within a controlled cell culture environment, focusing on nine different virus lineages. Our approach demonstrates how SARS-CoV-2 continues to evolve readily in vitro, with changes mirroring those seen in outbreak cases globally. Findings of the study are important for (i) investigating the mechanisms of how mutations arise, (ii) predicting the future evolutionary trajectory of SARS-CoV-2, and (iii) informing treatment and prevention design.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.00363-25?af=R

____

#Japan - #Influenza A #H5N2 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 A wild Peregrine falcon in Kagoshima Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6545

____

Multiple introductions of #equine #influenza virus into the #UK resulted in widespread #outbreaks and #lineage #replacement

Abstract

Influenza A viruses (IAVs) are prime examples of emerging viruses in humans and animals. IAV circulation in domestic animals poses a pandemic risk as it provides new opportunities for zoonotic infections. The recent emergence of H5N1 IAV in cows and subsequent spread over multiple states within the USA, together with reports of spillover infections in humans, cats and mice highlight this issue. The horse is a domestic animal in which an avian-origin IAV lineage has been circulating for >60 years. In 2018/19, a Florida Clade 1 (FC1) virus triggered one of the largest epizootics recorded in the UK, which led to the replacement of the Equine Influenza Virus (EIV) Florida Clade 2 (FC2) lineage that had been circulating in the country since 2003. We integrated geographical, epidemiological, and virus genetic data to determine the virological and ecological factors leading to this epizootic. By combining newly-sequenced EIV complete genomes derived from UK outbreaks with existing genomic and epidemiological information, we reconstructed the nationwide viral spread and analysed the global evolution of EIV. We show that there was a single EIV FC1 introduction from the USA into Europe, and multiple independent virus introductions from Europe to the UK. At the UK level, three English regions (East, West Midlands, and North-West) were the main sources of virus during the epizootic, and the number of affected premises together with the number of horses in the local area were found as key predictors of viral spread within the country. At the global level, phylogeographic analysis evidenced a source-sink model for intercontinental EIV migration, with a source population evolving in the USA and directly or indirectly seeding viral lineages into sink populations in other continents. Our results provide insight on the underlying factors that influence IAV spread in domestic animals.

Author summary

Influenza causes significant disease burden in animals, including wild birds, sea lions, pigs, horses, dogs, and more recently, cows. Outbreaks and epizootics of influenza in agricultural species are a threat to food security and the economy whereas in wild animals they could affect biodiversity and conservation efforts. Given the zoonotic nature of influenza viruses and the high levels of contact between domestic animals and humans, animal influenza is also a public health concern. Here, we combined geographical, epidemiological, and virus sequence data to determine key factors that led to one of the largest epizootics of equine influenza in the United Kingdom in decades. We show that an American equine influenza virus lineage was introduced into Europe and replaced the virus lineage that had been circulating in the United Kingdom for nearly 20 years. We also analysed a global dataset of virus genomes and propose a model of equine influenza virus intercontinental migration, in which USA is the main source of viruses to other countries. Our results provide important information concerning the basic principles of influenza virus circulation in animal populations. This is central to devise effective measures of disease control that would increase animal health while reducing zoonotic risk.

Source: PLoS Pathogens, https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013227

____

4th #meeting of #IHR (2005) Emergency #Committee regarding upsurge of #mpox 2024 – Temporary #recommendations (#WHO, June 9 '25)

Fourth meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox 2024 – Temporary recommendations

The Director-General of the World Health Organization (WHO), following the fourth meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the upsurge of mpox 2024, held on 5 June 2025, from 12:00 to 17:00 CEST, concurs with its advice that the event continues to meet the criteria of a public health emergency of international concern and, considering the advice of the Committee, he is hereby issuing a revised set of temporary recommendations.

The WHO Director-General expresses his most sincere gratitude to the Chair, Members, and Advisors of the Committee. The proceeding of the fourth meeting of the Committee will be shared with States Parties to the IHR and published in the coming days.

Temporary recommendations

These temporary recommendations are issued to States Parties experiencing the transmission of monkeypox virus (MPXV), including, but not limited to, those where there is sustained community transmission, and where there are clusters of cases or sporadic travel-related cases of MPXV clade Ib.

They are intended to be implemented by those States Parties in addition to the current standing recommendations for mpox, valid until 20 August 2025.

In the context of the global efforts to prevent and control the spread of mpox disease outlined in the WHO Strategic framework for enhancing prevention and control of mpox: 2024–2027, the aforementioned standing recommendations apply to all States Parties.

All current WHO interim technical guidance can be accessed on this page of the WHO website. WHO evidence-based guidance has been and will continue to be updated in line with the evolving situation, updated scientific evidence, and WHO risk assessment to support States Parties in the implementation of the WHO Strategic Framework for enhancing mpox prevention and control.

Pursuant to Article 3 Principle of the International Health Regulations (2005) (IHR), the implementation of these temporary recommendations, as well as of the standing recommendations for mpox, by States Parties shall be with full respect for the dignity, human rights and fundamental freedoms of persons, in line with the principles set out in Article 3 of the IHR.

Note: The text in backets next to each temporary recommendation indicates the status with respect to the set of temporary recommendations issued on 27 November 2024.

Emergency coordination

-- Secure political commitment and engagement to intensify mpox prevention and response efforts, including resource allocation, for the lowest administrative and operational level reporting mpox cases (hotspots) in the prior 4 weeks. (EXTENDED)

-- Establish or enhance national and local emergency prevention and response coordination arrangements as recommended in the WHO Mpox global strategic preparedness and response plan (2025), and its upcoming iteration, and in line with the WHO Strategic framework for enhancing prevention and control of mpox: 2024–2027. (EXTENDED, with updated reference)

-- Establish or enhance coordination among all partners and stakeholders engaged in or supporting mpox prevention and response activities through cooperation, including by introducing accountability mechanisms. (EXTENDED)

-- Establish a mechanism to monitor the effectiveness of mpox prevention and response measures implemented at lower administrative levels, so that such measures can be adjusted as needed. (EXTENDED)

-- Engage with and strengthen partner organizations for collaboration and support for mpox response, including humanitarian actors in contexts with insecurity, humanitarian corridors, or areas with internal or refugee population displacements and in hosting communities in insecure areas. (EXTENDED, with re-phrasing)

Collaborative surveillance

-- Enhance mpox surveillance, by increasing the sensitivity of the approaches adopted and ensuring comprehensive geographic coverage. (EXTENDED)

-- Expand access to accurate, affordable and available diagnostics to test for mpox, including through strengthening arrangements for the transport of samples, the decentralization of testing and arrangements to differentiate MPXV clades and conduct genomic sequencing. (EXTENDED)

-- Identify, monitor and support the contacts of persons with suspected, clinically-diagnosed or laboratory-confirmed mpox to prevent onward transmission. (EXTENDED)

-- Scale up efforts to thoroughly investigate cases and outbreaks of mpox to better understand the modes of transmission and transmission risk, and prevent its onward transmission to contacts and communities. (EXTENDED)

-- Report to WHO suspected, probable and confirmed cases of mpox in a timely manner and on a weekly basis. (EXTENDED)

Safe and scalable clinical care

-- Provide clinical, nutritional and psychosocial support for patients with mpox, including, where appropriate and possible, isolation in care centres and/or access to materials and guidance for home-based care. (EXTENDED)

-- Develop and implement a plan to expand access to optimized supportive clinical care for all patients with mpox, including children, pregnant women, and persons living with HIV, recognising the association of mpox-related morbidity and mortality in persons living with HIV with untreated or advanced HIV. This includes prompt identification and effective management of endemic co-infections, such as malaria, chickenpox or measles. This also includes offering HIV tests to adult patients who do not know their HIV status and to children as appropriate, testing and treatment for other sexually transmitted infections (STIs) among cases linked to sexual contact and referral to HIV/STIs treatment and care services when indicated. (EXTENDED, with re-phrasing)

-- Strengthen health and care workers’ capacity, knowledge and skills in clinical and infection and prevention and control pathways – screening, diagnosis, isolation, environmental cleaning, discharge of patients, including post discharge follow up for suspected and confirmed mpox –, and provide health and care workers with personal protective equipment (PPE). (EXTENDED)

-- Strengthen adherence to infection prevention and control (IPC) measures and availability of water, sanitation, hygiene (WASH) and waste management services and infrastructure in healthcare facilities and treatment and care centers to ensure quality healthcare service delivery and protection of health and care workers, caregivers and patients. (EXTENDED, with re-phrasing)

International traffic

-- Establish or strengthen cross-border collaboration arrangements for surveillance, management and support of suspected cases and contacts of mpox, and for the provision of information to travellers and conveyance operators, without resorting to travel and trade restrictions that unnecessarily impact local, regional or national economies. (EXTENDED)

Vaccination

-- Continue to prepare for and implement targeted use of vaccine for “Phase 1-Stop the outbreak” (as defined in the WHO Mpox global strategic preparedness and response plan (2025)) through the identification of the lowest administrative level reporting cases (hotspots) and targeting those groups at high risk of mpox exposure to interrupt sustained community transmission. (EXTENDED, with rephrasing and updated reference)

-- Develop and implement plans for vaccination in the context of an integrated response at the lowest administrative level reporting cases for people at high risk of exposure (e.g., contacts of cases of all ages, health and frontline workers, and other groups at risk such as those with multiple sexual partners and sex workers in endemic and non-endemic areas). This entails a targeted integrated response, including active surveillance and contact tracing; agile adaptation of immunization strategies and plans to the local context including dose-sparing options (single dose/fractional dosing) in the context of limited availability of vaccines; proactive community engagement to generate and sustain demand for and trust in vaccination; close monitoring of mpox vaccination activities, coverage and adverse events following immunization (AEFI); assessment of vaccine effectiveness; and documenting lessons learned and their implementation. (MODIFIED)

Community protection

-- Strengthen risk communication and community engagement in affected communities and local workforces for outbreak prevention, response and vaccination strategies, particularly at the lowest administrative levels reporting cases. Key actions include training, mapping high risk and vulnerable populations for tailored interventions, data driven approaches for social listening, community feedback and dialogue, and managing misinformation. This entails, inter alia, communicating effectively the uncertainties and new information regarding the natural history of mpox and modes of transmission, the effectiveness of mpox vaccines and duration of protection following vaccination, and about any clinical trials to which the local population may have access, as appropriate. (EXTENDED, with re-phrasing)

-- Address stigma and discrimination of any kind via meaningful community engagement, particularly in health services and during risk communication activities, and through engagement with civil society groups, such as HIV networks. (EXTENDED, with re-phrasing)

-- Promote and implement IPC measures and basic WASH and waste management services in household settings, congregate settings (e.g. prisons, internally displaced persons and refugee camps, etc.), schools, points of entry and cross border transit areas. (EXTENDED)

Governance and financing

-- Galvanize and scale up national funding and explore external opportunities for targeted funding of mpox prevention, readiness and response activities, advocate for release of available funds and take steps to identify potential new funding partners for emergency response. (EXTENDED)

-- Optimize the use of resources, in the context of global and local external funding shortfalls, by allocating available resources to the implementation of core mpox response interventions needed in the medium term; maximizing their cost-efficiency through cross-programmatic synergetic approaches; and by engaging partners in resource-sharing arrangements to maintain the delivery of essential health services. (NEW)

-- Integrate mpox prevention and response measures, including enhanced surveillance, in existing programmes for prevention, control and treatment of other endemic diseases – especially HIV, as well as STIs, malaria, tuberculosis and other vaccine-preventable diseases, and/or non-communicable diseases – striving to identify activities which will benefit the programmes involved and lead to better health outcomes overall. (EXTENDED)

Addressing research gaps

-- Invest in addressing outstanding knowledge gaps and in generating evidence, during and after outbreaks, as defined in A coordinated research roadmap – Mpox virus - Immediate research next steps to contribute to control the outbreak (2024), including for vaccine effectiveness in different contexts. (EXTENDED, with re-phrasing)

-- Invest in field studies to better understand animal hosts and zoonotic spillover in the areas where MPXV is circulating, in coordination with the animal health sector and One Health partners. (EXTENDED)

-- Strengthen and expand use of genomic sequencing to characterize the epidemiology and chains of transmission of MPXV to better inform control measures, particularly regarding the emergence and circulation of new virus strains. (EXTENDED, with re-phrasing)

Reporting on the implementation of temporary recommendations

-- Report quarterly to WHO on the status of, and challenges related to, the implementation of these temporary recommendations, using a revised standardized tool and channels that will be made available by WHO, also allowing for the monitoring of progress and the identification of gaps of the national response. (EXTENDED, with re-phrasing)

___

Source: World Health Organization, https://www.who.int/news/item/09-06-2025-fourth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-upsurge-of-mpox-2024-temporary-recommendations

_____

E627V #mutation in #PB2 protein promotes the #mammalian #adaptation of novel #H10N3 avian #influenza virus

Abstract

Since 2021, the novel H10N3 has caused four cases of human infection in China, the most recent of which occurred in December 2024, posing a potential threat to public health. Our previous studies indicated that several avian H10N3 strains are highly pathogenic in mice and can be transmitted between mammals via respiratory droplets without prior adaptation. By analyzing the genome sequence, we found that these H10N3 viruses carry the PB2-E627V mutation, which is becoming increasingly common in several subtypes of avian influenza viruses (AIV); however, its mechanism in mammalian adaptation remains unclear. Using a reverse genetics system, we investigated the role of PB2-E627V in the adaptation of H10N3 to mammals and poultry. Our findings demonstrate that the PB2-E627V mutation is critical for the high pathogenicity of novel H10N3 in mice and its ability to be transmitted through the air among mammals. Additionally, we found that the role of PB2-627 V in promoting AIV adaptation to mammals is comparable to that of PB2-627 K. More importantly, PB2-627 V appears to be equally suited to long-term persistence in poultry. Therefore, using PB2-627 V as a novel molecular marker to assess the epidemic potential of AIV is of great significance for preventing possible influenza pandemics in the future.

Source: Veterinary Research, https://veterinaryresearch.biomedcentral.com/articles/10.1186/s13567-025-01534-8

____

Death of Actaeon, Titian (1559 - 1575)

 

Public Domain.

Source: WikiArt, https://www.wikiart.org/en/titian/death-of-actaeon-1562

____